CD86 and neoplasm: It is possible to speculate that overexpression of antigen presentation molecules (e.g. MHC-I and II) and co-stimulatory molecules (e.g. CD80 and CD86) can enhance anti-tumour immune response [71, 72] in the melanoma model.